The recognition of toxoplasmosis as a life threatening infection of the immunocompromised, and greater awareness of congenital toxoplasmosis, have emphasised the need for reliable methods of diagnosing this parasitic infection. The Sabin and Feldman dye test is still the serological test of choice,' but this technically demanding bioassay is rarely performed outside reference centres.
The peripheral laboratory requires a reliable screening test for toxoplasmosis, while the reference laboratory may choose to run a second assay in parallel with the dye test to minimise erroneous results when large numbers of samples are processed. The latex agglutination test (Eiken Chemical Company, Tokyo) is widely used in this context. Previous studies have confirmed the suitability of this assay as a screening test2 but have documented a significant incidence of false positive results.3
In France, where the experience of toxoplasma infection is greater than that in the United Kingdom, a commercial direct agglutination test is in widespread use. The original direct agglutination test, described by Fulton and Turk, entailed the reaction of specific antibody with formalin-fixed, toxoplasma tachyzoites. 4 The method lacked sensitivity, producing lower titres than those recorded by the dye test, and gave false positive reactions due to the binding ofnonAccepted for publication 12 Jamuary 1989 toxoplasma specific IgM immunoglobulin to the parasite. Subsequent modifications of the technique suppressed non-specific reactions by the use of 2-mercaptoethanol buffer and increased sensitivity by treatment of the tachyzoites with trypsin, producing a "sensitised" antigen.' As the modified test is now available to laboratories in the United Kingdom we assessed the performance ofthis assay and compared it with the dye test and the latex agglutination test.
Material and methods
Four hundred stored sera, previously assayed with the dye test were selected for inclusion in the trial. The Toxo-Screen direct agglutination test kit is used for the detection of toxoplasma IgG antibodies by direct agglutination using a sensitised antigen and is produced by BioMerieux, France. IgM-mediated agglutination is suppressed by using a diluting buffer containing 2-mercaptoethanol. The assay was supplied as a kit containing 4 ml of a suspension of Toxoplasma gondii treated with formalin and obtained from mouse ascitic fluid, 16 ml of diluent (BABS colour buffer), 1 ml of concentrated 2-mercaptoethanol which was diluted to give a 0-2 mol/l solution, lyophilised positive and negative control sera (each to be diluted to 1 ml) and powdered phosphate buffered saline (PBS) to be diluted to one litre. Four microtitration plates, four self-adhesive plate covering sheets, and four report sheets were also included in the kit.
If the antigen is used as recommended-that is, diluted to 1 in 5 with diluent, 50 MI per well, sufficient is provided for 400 wells. The kit has a shelf life of six months when stored at 2°C-8'C. Two different antigen batches were used during the course of the study.
The test was performed in microtitre plates (ushaped wells). For screening the sera, two dilutions were prepared: a 1 in 20 (100 pi serum + 1-9 ml PBS) and a I in 2000 dilution (25 p1 of the 1 in 20 dilution + 2-5 ml of PBS). Each dilution (25 p1) was transferred into the microtitre trays and 25 p1 of 0-2 mol/l 2-mercaptoethanol added to each well, thus diluting the sera I in 40 and 1 in 4000. The antigen (50 p1) diluted 1 in 5 with the diluent was added to each well, the plate covered with a self-adhesive sheet, mixed thoroughly and left to stand at room temperature overnight. The Toxoplasma National Control Serum and a positive control ofknown titre were run with every batch of test sera. Agglutination patterns were determined using a mirrored plate reader.
A positive reaction exhibits agglutination of the toxoplasma in a mat covering about half of the well base. In the absence of specific antibody a compact button wasg obtained. A Johnson, Duffy, New, Holliman, Chessum, Fleck --19------2 9---25--.24---19--21---13--4----1--3--- The current study has shown that neither the presence of anti-nuclear factor nor rheumatoid factor in sera had a demonstrable effect on the performance of any of the three assays. We have previously shown that neither cytomegalovirus infection, inactivation of the sera, kit batch variation nor the presence of hepatitis B virus "e" antigen in the sample are consistently associated with discordant latex agglutination test reactions. 3 The direct agglutination test should be regarded as an alternative to the latex agglutination test for use in the diagnosis oftoxoplasma infection. When considering which assay to utilise, the laboratory should define its own requirements of the test to be used. When optimal sensitivity is needed and reduced specificity can be accepted, then the latex agglutination test would be a rational choice. Alternatively, if specificity is the dominant concern then the use of the direct agglutination test would be appropriate. In many instances the small differences in sensitivity and specificity between the two tests would be of little clinical importance and the laboratory's choice would be based on additional factors such as cost, availability, and user preference. The investigation of immunocompromised patients at risk of life threatening toxoplasmosis (fetus, those with malignancy, or human immunodeficiency virus infection, and transplant recipients) requires detailed examination with additional tests. Samples taken from these patients should be considered for referral to a reference centre, irrespective of the findings in the primary laboratory.
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Toxo-screen direct agglutination test kits were provided by API-BioMerieux (UK) Limited, Basingstoke, Hampshire.
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